Breast Cancer Clinical Trial

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy

Summary

The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which includes either pembrolizumab or pembrolizumab plus capecitabine in participants with triple negative breast cancer that still remains after surgery and pre-surgical treatment.

View Eligibility Criteria

Eligibility Criteria

Key Inclusion Criteria:

Age > 18 years, with residual invasive triple negative breast cancer (TNBC) in the breast or lymph nodes after neoadjuvant therapy and surgery:

TNBC criteria for the study is defined as estrogen receptor (ER) and progesterone receptor (PR) < 10%, human epidermal growth factor receptor 2 (HER2)-negative per American Society of Clinical Oncology and College of American Pathologists (ASCO/CAP) guidelines (immunohistochemistry (IHC) and/or in situ hybridization (ISH)).
Adequate excision and surgical removal of all clinically evident of disease in the breast and/or lymph nodes and have adequately recovered from surgery.
Submission of both pre-neoadjuvant treatment diagnostic biopsy and resected residual invasive disease tissue.
Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
Individuals must have received appropriate radiotherapy and have recovered prior to starting study treatment.
Adequate organ function.

Key Exclusion Criteria:

Stage IV (metastatic) breast cancer as well as history of any prior (ipsi- or contralateral) invasive breast cancer.
Prior treatment with another stimulatory or coinhibitory T-cell receptor agent (eg, cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), OX-40, cluster of differentiation 137 (CD137), prior treatment with any HER2-directed agent.
Evidence of recurrent disease following preoperative therapy and surgery.
Prior treatment with topoisomerase 1 inhibitors or antibody-drug conjugates (ADCs) containing a topoisomerase inhibitor.
Individuals with known germline breast cancer gene (BRCA) mutations.
Myocardial infarction or unstable angina pectoris within 6 months of enrollment or history of serious ventricular arrhythmia (ie, ventricular tachycardia or ventricular fibrillation), high-grade atrioventricular block, or other cardiac arrhythmias or Left ventricular ejection fraction (LVEF) of < 50%
Active serious infections requiring anti-microbial therapy.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Study is for people with:

Breast Cancer

Phase:

Phase 3

Estimated Enrollment:

1514

Study ID:

NCT05633654

Recruitment Status:

Recruiting

Sponsor:

Gilead Sciences

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 22 Locations for this study

See Locations Near You

Alabama Oncology
Birmingham Alabama, 35243, United States
Clearview Cancer Institute
Huntsville Alabama, 35805, United States
Palo Verde Hematology Oncology
Glendale Arizona, 85304, United States
Compassionate Cancer Care Medical Group - Inc
Fountain Valley California, 92708, United States
Los Angeles Cancer Network
Los Angeles California, 90017, United States
Emad Ibrahim, MD, INC
Redlands California, 92373, United States
Stamford Hospital
Stamford Connecticut, 06902, United States
Cancer Specialists of North Florida
Jacksonville Florida, 32256, United States
Piedmont Cancer Institute
Atlanta Georgia, 30318, United States
Northside Hospital
Atlanta Georgia, 30342, United States
Northwest Georgia Oncology Centers, PC
Marietta Georgia, 30060, United States
Medstar Franklin Square Medical Center
Baltimore Maryland, 21237, United States
American Oncology Partners of Maryland, PA
Bethesda Maryland, 20817, United States
Regional Cancer Care Associates LLC
East Brunswick New Jersey, 08816, United States
Summit Medical Group, P.A.
Florham Park New Jersey, 07932, United States
San Juan Oncology Associates
Farmington New Mexico, 87401, United States
Clinical Research Alliance
Westbury New York, 11590, United States
Monument Health Cancer Care Institute
Rapid City South Dakota, 57701, United States
Avera Cancer Institute
Sioux Falls South Dakota, 57105, United States
University of Tennessee
Knoxville Tennessee, 37920, United States
Northwest Medical Specialties, PLLC
Puyallup Washington, 98373, United States
Medical Oncology Associates
Spokane Washington, 99208, United States

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Phase:

Phase 3

Estimated Enrollment:

1514

Study ID:

NCT05633654

Recruitment Status:

Recruiting

Sponsor:


Gilead Sciences

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.